Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically homozygous for the atypical plasma cholinesterase variant: Effect of injection of human cholinesterase

Anesthesiology

Volumn 102, Issue 6, 2005, Pages 1124-1132

  Østergaard, Doris ^a,f   Viby Mogensen, Jørgen ^b,f   Rasmussen, Søren N ^d,f   Gätke, Mona R ^c,f   Varin, France ^e,f  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Danish Cholinesterase Research Unit   (Denmark)

^c Rigshospitalet   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; CENTEON; CHOLINESTERASE; DIAZEPAM; FENTANYL; MIVACURIUM; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; NITROUS OXIDE; PROPOFOL; THIOPENTAL;

ADOLESCENT; ADULT; AGED; ANESTHESIA INDUCTION; ANESTHETIC RECOVERY; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; DRUG EFFECT; ELECTIVE SURGERY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MALE; NEUROMUSCULAR BLOCKING; PHARMACODYNAMICS; PHENOTYPE; PRIORITY JOURNAL; SURGICAL PATIENT;

ADOLESCENT; ADULT; CHOLINESTERASES; FEMALE; HOMOZYGOTE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; PHENOTYPE; VARIATION (GENETICS);

EID: 19744364810     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200506000-00011     Document Type: Article

References (32)

1. Savarese JJ, Ali HH, Basta SJ, Embree PB, Scott RPF, Sunder N, Weakly JN, Wastila WB, El-Sayad HA: The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). ANESTHESIOLOGY 1988; 68:723-32
2. Lien CA, Schmith VD, Embree PB, Belmont MR, Wargin WA, Savarese JJ: The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ANESTHESIOLOGY 1994; 80:1296-302
3. Østergaard D, Jensen FS, Skovgaard LT, Viby-Mogensen J: Dose-relationship for mivacurium in patients with atypical plasma cholinesterase. Acta Anesthesiol Scand 1995; 39:1016-8
4. Østergaard D, Jensen FS, Jensen E, Skovgaard LT, Viby-Mogensen J: Mivacurium induced neuromuscular blockade in patients with atypical plasma cholinesterase. Acta Anaesthesiol Scand 1993; 37:314-8
5. Goudsouzian NG, d'Hollander AA, Viby-Mogensen J: Prolonged neuromuscular block from mivacurium in two patients with cholinesterase deficiency. Anesth Analg 1993; 77:183-5
6. Maddineni VR, Mirakhur RK: Prolonged neuromuscular block following mivacurium. ANESTHESIOLOGY 1993; 78:1181-4
7. Petersen RS, Bailey PL, Kalameghan R, Adhwood ER: Prolonged neuromuscular block after mivacurium. Anesth Analg 1993; 76:194-6
8. Østergaard D, Jensen FS, Viby-Mogensen J: Reversal of intense mivacurium block with human plasma cholinesterase in patients with atypical plasma cholinesterase. ANESTHESIOLOGY 1995; 82:1295-8
9. Naguib M, El-Gammal M, Daoud W, Ammar A, Moukthar H, Turkistani A: Human plasma cholinesterase for the antagonism of prolonged mivacurium-induced neuromuscular blockade. ANESTHESIOLOGY 1995; 82:1288-92
10. Jensen FS, Viby-Mogensen J: Plasma cholinesterase and abnormal reaction to succinylcholine: Twenty years' experience with the Danish Cholinesterase Research Unit. Acta Anaesthesiol Scand 1995; 39:150-56
11. Jensen FS, Skovgaard LT, Viby-Mogensen J: Identification of human plasma cholinesterase variants in 6.688 individuals using biochemical analysis. Acta Anaesthesiol Scand 1995; 39:157-62
12. Viby-Mogensen J, Engbask J, Eriksson LI, Gramstad L, Jensen E, Jensen FS, Koscielniak-Nielsen Z, Skovgaard LT, Østergaard D: Good clinical research practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents. Acta Anaesthesiol Scand 1996; 40:59-74
13. Viby-Mogensen J, Østergaard D, Donati F, Fisher D, Hunter J, Kampmann JP, Kopman A, Proost JH, Rasmussen SN, Skovgaard LT, Varin F, Wright PMC: Pharmacokinetic studies of neuromuscular blocking agents: Good clinical research practice (GCRP). Acta Anaesthesiol Scand 2000; 44:1169-90
14. DÁrgenio DZ, Schumitzky A: A program packager for simulation and parameter estimation in pharmacokinetics. Comput Programs Biomed 1979; 9:115-34
15. Holford NH, Sheiner LB: Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinetics 1981; 6:429-53
16. Østergaard D, Rasmussen SN, Viby-Mogensen J, Pedersen NA, Boysen R: The influence of drug-induced low plasma cholinesterase activity on the pharmacokinetics and pharmacodynamics of mivacurium. ANESTHESIOLOGY 2000; 92: 1581-7
17. Naguib M, Samarkandi AH, Bakhamees HS, Turkistani A, Alharby SW: Edrophonium and human plasma cholinesterase combination for antagonism of mivacurium-induced neuromuscular block. Br J Anaesth 1996; 77:424-6
18. Gätke MR, Østergaard D, Bundgaard J, Varin F, Viby-Mogensen J: Response to mivacurium in a patient compound heterozygous for a novel and a known silent mutation in the butyrylcholinesterase gene. ANESTHESIOLOGY 2001; 95:600-6
19. Viby-Mogensen J: Correlation of succinylcholine duration of action with plasma cholinesterase activity in subjects with genotypically normal enzyme. ANESTHESIOLOGY 1980; 53:517-20
20. Lien CA, Belmont MR, Wray Roth DL, Okamoto M, Abalos A, Savarese JJ: Pharmacodynamics and the plasma concentration of mivacurium during spontaneous recovery and neostigmine-facilitated recovery. ANESTHESIOLOGY 1999; 91: 119-26
21. Naguib M, Selim M, Bakhamees HS, Samarkandi AH, Turstani A: Enzymatic versus pharmacologic antagonism of profound mivacurium-induced neuromuscular blockade. ANESTHESIOLOGY 1996; 84:1051-9
22. Kao YJ, Le ND: The reversal of profound mivacurium-induced neuromuscular blockade. Can J Anaesth 1996; 43:1128-33
23. Kopman AF, Mallhi MU, Justo MD, Rodricks P, Neuman GG: Antagonism of mivacurium-induced neuromuscular blockade in humans. ANESTHESIOLOGY 1994; 81:1394-400
24. Head-Rapson AG, Devlin JC, Parker CJR, Hunter JM: Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. Br J Anaesth 1995; 75:31-6
25. Head-Rapson AG, Devlin JC, Parker CJR, Hunter JM: Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. Br J Anaesth 1994; 73:613-8
26. Devlin JC, Head-Rapson AG, Parker CJR, Hunter JM: Pharmacodynamics of mivacurium chloride in patients with hepatic cirrhosis. Br J Anaesth 1993; 71:227-31
27. Laurin J, Nekka F, Donati F, Varin F: Assuming peripheral elimination: Its impact on the estimation of pharmacokinetic parameters of muscle relaxants. J Pharmacokinet Biopharm 1999; 27:491-512
28. Szenohradszky J, Lau M, Brown R, Sharma ML, Fisher DM: The effect of neostigmine on twitch tension and muscle relaxant concentration during infusion of mivacurium or vecuronium. ANESTHESIOLOGY 1995; 83:83-7
29. Laurin J, Donati F, Varin F: Stereoselective in vitro degradation pattern of mivacurium in human plasma. Br J Anaesthesia 2002; 89:832-8
30. Schiere S, Proost JH, Roggeveld J, Wierda M: An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. Eur J Anaesthesiol 2004; 21:882-91
31. Laurin J, Donati F, Nekka F, Varin F: Peripheral link model as an alternative for pharmacokinetic-pharmacodynamic modeling of drugs having a very short elimination half-life. J Pharmacokinet Pharmacodyn 2001; 28:7-25
32. Lacroix M, Donati F, Varin F: Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration. ANESTHESIOLOGY 1997; 86:322-30